Sign In

7.1 : Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the NMJ, action potential arises, and impulse transmission across the NMJ facilitates skeletal muscle contractions.

As the nerve impulse arrives at the synaptic bulb ends, it stimulates Ca2+ influx by opening the calcium channels, which stimulates exocytosis of the synaptic vesicles and release of acetylcholine in the synaptic cleft. Two acetylcholine molecules bind to the receptor at the motor end plate, opening Na+ channels. Na+ influx inside the muscle fiber changes the membrane potential, triggering a muscle action potential followed by muscle contraction. The effect of acetylcholine is brief as the enzyme acetylcholinesterase breaks down acetylcholine into choline and acetate.

Certain agents can block the events at the NMJ to prevent muscle contraction. Botulinum toxin prevents exocytosis of the synaptic vesicles, preventing acetylcholine release. Tubocurarine and other neuromuscular blockers can limit impulse transmission across the NMJ by binding to acetylcholine receptors. This is important for treating several pathological conditions and for use during patient surgeries to induce muscle relaxation and temporary paralysis.

Tags
Neuromuscular JunctionNMJMotor NeuronMuscle FiberAcetylcholineNeurotransmitterAction PotentialSynaptic End BulbsMotor End PlateCalcium ChannelsExocytosisSynaptic CleftMuscle ContractionAcetylcholinesteraseBotulinum ToxinNeuromuscular Blockers

From Chapter 7:

article

Now Playing

7.1 : Neuromuscular Junction And Blockade

Skeletal Muscle Relaxants

1.9K Views

article

7.2 : Classification of Skeletal Muscle Relaxants

Skeletal Muscle Relaxants

2.1K Views

article

7.3 : Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Skeletal Muscle Relaxants

972 Views

article

7.4 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Skeletal Muscle Relaxants

276 Views

article

7.5 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

Skeletal Muscle Relaxants

356 Views

article

7.6 : Depolarizing Blockers: Mechanism of Action

Skeletal Muscle Relaxants

839 Views

article

7.7 : Depolarizing Blockers: Pharmocokinetics

Skeletal Muscle Relaxants

228 Views

article

7.8 : Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Skeletal Muscle Relaxants

433 Views

article

7.9 : Skeletal Muscle Relaxants: Adverse Effects

Skeletal Muscle Relaxants

251 Views

article

7.10 : Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants

380 Views

article

7.11 : Spasmolytic Agents: Chemical Classification

Skeletal Muscle Relaxants

765 Views

article

7.12 : Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal Muscle Relaxants

2.7K Views

article

7.13 : Centrally Acting Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants

395 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved